Click the title to jump to your preferred section:

StroMed Osteoarthritis Knee Outcomes

At Cell-Innovations all Doctors and clinics that use our technology continually track the outcomes from patients and have all shown excellent outcomes for their patients. The analysis by our doctors is made possible by the large number of patients (over 800) who have sought stem cell treatment rather than have knee or hip surgery.

Examples of tissue regeneration occurring in the knees of patients are shown in the MRI studies below. Cell-Innovation is constantly improving the use of StroMed to advance consistent tissue regeneration. Please note that the results of every procedure will vary from patient to patient. There is no guarantee you will have tissue regeneration.

Not all patients will respond to stem cell treatment with StroMed results indicating that whilst most knee osteoarthritis patients will be Responders some will be non-responders to the treatment.

Importantly Cell-Innovations now has a simple proprietary test to indicate whether you will likely respond to stem cell treatment for your Osteoarthritis saving the patient undergoing liposuction procedure and fees for treatment if you are classified as a non-responder to stem cell treatment. Talk to your Doctor to have this test.

NB: the data presented below is a compilation of patient outcomes from in-house studies following StroMed treatment.

In 80 knee osteoarthritis patients at 1 year post-StroMed treatment there is an average improvement of 78%

chart

No two patients are alike and patients will vary in their response to StroMed

stromed

MRI coronal images of the knee. The black area underneath the top knee bone indicates cartilage depth. By week 16 a sizeable increase in the regenerated tissue is observed.

MRI

MRI coronal images of the knee. The black area underneath the top knee bone indicates cartilage depth. By week 16 a sizeable increase in the regenerated tissue is observed.

diagram

MRI sagittal images of the knee. The black area underneath the top knee bone indicates cartilage depth. By week 16 a sizeable increase in the regenerated tissue is observed.

diagram_2

The reduction in pain that occurs over time following StroMed treatment may also lead to Doctors recommending patients reduce or stop their anti-inflammatory or pain medication

Note: Any case reports or patient results presented on this web-site are not indicative of all patient results. Like any medical procedure, all regenerative procedures have a success and failure rate.

Osteoarthritis Hip Outcomes

At Cell-Innovations all Doctors and clinics that use our technology continually track the outcomes from patients and have all shown excellent outcomes for their patients.

Patients who have StroMed for osteoarthritis of the hips have demonstrated a very good improvement in their osteoarthritis scores.

Not all patients will respond to stem cell treatment with StroMed results indicating that approximately most will be Responders and a small group non-responders to the treatment.

Importantly Cell-Innovations now has a simple proprietary test to indicate whether you will likely respond to stem cell treatment for your Osteoarthritis saving the patient undergoing liposuction procedure and fees for treatment if you are classified as a non-responder to stem cell treatment. Talk to your Doctor to have this test.

NB: the data presented below is a compilation of patient outcomes from in-house studies following StroMed treatment.

Migraine Outcomes

Cell-Innovations has recently pioneered the work into the treatment of chronic migraines by the use of StroMed. Sufferers of chronic migraines typically have more than 15 migraines or tension-type headaches per month. Cell-innovations study has shown the potency of this treatment on those people who are at the extreme end of the disease.

Of the 4 chronic migraine patients treated 3 out of the 4 patients obtained long term relief from migraines for up to 12 – 18 months with a decrease of more than 95% of migraines and tension-type headaches during the study. It is still unknown how long the effects of the treatment will be for or whether further treatments will be required.

Below is a copy of the Abstract published and complete article. Cell-Innovation clinics are the only licensed clinics to use this procedure.

Migraine and tension-type headache treated with stromal vascular fraction: a case series.Journal of Medical Case Reports 2014, 8:237

Abstract

Introduction
Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition, the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for both patients and physicians.

Case presentations
Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the
frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month.
Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal anti-inflammatory drugs and paracetamol.

Conclusions
This case series is the first to provide evidence of the efficacy of autologous StroMed and stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment that may help address the symptoms of the disease. Given what is known about the components of the stromal vascular fraction and how they act, the information presented in this case series may also further our knowledge of the etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely effective and has been life changing for these…

The full report is available at the Journal of Medical Case Reports 2014, 8:237 Migraine and tension-type headache treated with stromal vascular fraction: a case series

References

A recent paper presented by Dr Michalek at the 2013 International Federation for Adipose Therapeutics and Science meeting in New York revealed successful results of cell therapy for patients suffering from osteoarthritis

Since 2011, a total of 275 patients have been recruited and followed for up to 24 months to demonstrate the therapeutic potential of freshly isolated SVF cells. At the same time, one to four joints (knees and hips) were injected with SVF cells per patient. A total number of 433 joints were treated.

Within 1-2 weeks from SVF therapy 85% of patients were off the non-steroid analgesics and remained off these analgesics for at least 6 months. After 3 months from SVF therapy, at least 50% clinical improvement was recognized in 95%, at least 75% clinical improvement in 68%, and complete remission in 54% of patients, respectively. Within 1-2 weeks from SVF therapy 85% of patients were off the non-steroid analgesics and remain such for at least 6 months. No serious side effects, infection or cancer was associated with SVF cell therapy.

Semiquantitative clinical scale evaluation and non-steroid analgesics dependence was used as measurement of the clinical effect. Prior to testing, all patients were diagnosed with stage II-IV osteoarthritis using X-ray and ultrasound, in some cases MRI was also performed to monitor the changes before and after stem cell therapy.

This work was supported in part by the International Consortium for Cell Therapy and Immunotherapy and Czech Ministry of Education.

Mickalek J, et al, Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transplant. 2015 Jan 20. doi: 10.3727/096368915X686760

Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis

Almost all patients showed significant improvement in all clinical outcomes at the final follow-up examination. All clinical results significantly improved at 2-year follow-up compared to 12-month follow-up (P < 0.05). Among elderly patients aged >65 years, only five patients demonstrated worsening of Kellgren-Lawrence grade. On second-look arthroscopy, 87.5 % of elderly patients (14/16) improved or maintained cartilage status at least 2 years postoperatively. Moreover, none of the patients underwent total knee arthroplasty during this 2-year period.

Koh et al, Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015 May;23(5):1308-16. doi: 10.1007/s00167-013-2807-2.

Knee Osteoarthritis

Meniscus Repair

Osteoarthritis of Hips

Tendons

Cited References

  1. Moseley, T.A.., M. Zhu, and M.H. Hedrick. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 121S-128S.
  2. Rodriguez, J..P., et al., Autologous stromal vascular fraction on therapy for rheumatoid arthritis rationale and clinical safety. Int Arch Med, 2012. 5: p. 5.
  3. NIH webpage: Information on stem cells
  4. Karp, J.M. and G.S. Leng Teo, Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell, 2009. 4(3): p. 206-16
  5. MacFarlane, R.J., et al., An -inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets, 2013. 17(3): p. 243-54.
  6. Han, J., et al., Adipose tissue is an extramedullary reservoir for functional hematopoiec stem and progenitor cells. Blood,2010. 115(5): p. 957-64
  7. Zuk, P.A., The adipose-derived stem cell: looking back and looking ahead. Mol Biol Cell, 2010. 21(11): p. 1783-7.
  8. Chen, H.T., et al., Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med,2012.16(3): p.582-93.
  9. Lin RZ. Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci U S A. 2014 Jun 30
  10. Riordan NH. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

More Information

Independent University Verification
Clinical Trials